Can the response to 23-valent pneumococcal vaccine in splenectomised patients be predicted?

被引：5
|
作者：
Llupia, Anna [1 ]
Vilella, Anna [1 ]
Costas, Laura [2 ]
Diez, Consolacion [1 ]
Torres, Ferran [3 ,4 ]
Yaguee, Jordi [5 ]
Masso, Montserrat [5 ]
Munoz, Ana [6 ]
Mensa, Josep [6 ]
机构：
[1] Hosp Clin Barcelona, Prevent Med & Epidemiol Dept, E-08036 Barcelona, Catalonia, Spain
[2] IDIBELL, Inst Catala Oncol, Canc Epidemiol Res Programme, Infect & Canc Unit UNIC, Lhospitalet De Llobregat 08908, Catalonia, Spain
[3] Hosp Clin Barcelona, IDIBAPS, Stat & Methodol Support Unit USEM, E-08036 Barcelona, Catalonia, Spain
[4] Univ Autonoma Barcelona, Sch Med, Biostat Unit, E-08193 Barcelona, Catalonia, Spain
[5] Hosp Clin Barcelona, Dept Immunol, E-08036 Barcelona, Catalonia, Spain
[6] Hosp Clin Barcelona, Dept Infect Dis, E-08036 Barcelona, Catalonia, Spain
来源：
VACCINE | 2012年 / 30卷 / 13期
关键词：
Splenectomy; Streptococcus pneumoniae; Response to vaccination; POLYSACCHARIDE VACCINE; ANTIBODY-RESPONSES; IMMUNOGLOBULIN-G; TRAUMA PATIENTS; INFECTION; ADULTS; IGG; VACCINATIONS; LYMPHOMA;
D O I：
10.1016/j.vaccine.2011.09.073
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The 23-valent pneumococcal vaccine has unequal effectiveness in splenectomised patients. We performed a longitudinal study (2005-2008) whose main objective was to characterize the profile of non-responders among splenectomised patients treated at our institution and identify potential predictive indicators of the response to the vaccine. The immune response was evaluated in 96 subjects. The proportion of responders was 70% (95% Cl: 60-78%). Immunosuppression (OR=3.19, 95% Cl 1.04-9.73) and the reason for splenectomy (hematologic neoplasia versus non-malignant hematologic diseases, OR=7.37, 95% CI 1.71-31.7) were independent predictors of non-response to vaccination. However, the positive predictive value of the model and the likelihood ratio for a positive result were low (PPV = 76.6%, 95% Cl 66.2-84.4%, LR(+)=1.41,95% Cl 1.08-1.86). We recommend determining the response to pneumococcal vaccine in these patients when possible. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2382 / 2386
页数：5
相关论文
共 50 条
  • [31] Kinetics of IgM and IgA Antibody Response to 23-Valent Pneumococcal Polysaccharide Vaccination in Healthy Subjects
    Schuetz, Katharina
    Hughes, Richard G.
    Parker, Antony
    Quinti, Isabella
    Thon, Vojtech
    Cavaliere, Monica
    Wuerfel, Martina
    Herzog, Wilhelm
    Gessner, J. Engelbert
    Baumann, Ulrich
    JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 (01) : 288 - 296
  • [32] Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations
    Wang, Yang
    Li, Jingxin
    Wang, Yuxiao
    Gu, Wei
    Zhu, Fengcai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (04) : 1003 - 1012
  • [33] The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial
    Izumi, Yasumori
    Akazawa, Manabu
    Akeda, Yukihiro
    Tohma, Shigeto
    Hirano, Fuminori
    Ideguchi, Haruko
    Matsumura, Ryutaro
    Miyamura, Tomoya
    Mori, Shunsuke
    Fukui, Takahiro
    Iwanaga, Nozomi
    Jiuchi, Yuka
    Kozuru, Hideko
    Tsutani, Hiroshi
    Saisyo, Kouichirou
    Sugiyama, Takao
    Suenaga, Yasuo
    Okada, Yasumasa
    Katayama, Masao
    Ichikawa, Kenji
    Furukawa, Hiroshi
    Kawakami, Kenji
    Oishi, Kazunori
    Migita, Kiyoshi
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [34] Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea
    Kang, Dong-Won
    Kim, Chae-Rin
    Song, Joon Young
    Park, Sun-Kyeong
    VACCINE, 2024, 42 (04) : 871 - 878
  • [35] Antibody responses in postsplenectomy trauma patients receiving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days postoperatively
    Shatz, DV
    Romero-Steiner, S
    Elie, CM
    Holder, PF
    Carlone, GM
    JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2002, 53 (06): : 1037 - 1042
  • [36] Evaluation of effectiveness, safety and cost-benefit of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients
    Zou, Xiaobai
    He, Jianmei
    Zheng, Jun
    Liang, Mengran
    Gao, Jinjin
    Huang, Jianwen
    Jiang, Yang
    Jiang, Yonglin
    Chen, Xi
    VACCINE, 2022, 40 (01) : 37 - 42
  • [37] Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
    Schmoele-Thoma, Beate
    van Cleeff, Martin
    Greenberg, Richard N.
    Gurtman, Alejandra
    Jones, Thomas R.
    Sundaraiyer, Vani
    Gruber, William C.
    Scott, Daniel A.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 575 - 583
  • [38] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis
    Vadlamudi, Nirma Khatri
    Parhar, Kamalpreet
    Malana, Kim Lorenzo Altre
    Kang, Amy
    Marra, Fawziah
    VACCINE, 2019, 37 (08) : 1021 - 1029
  • [39] Antigen-Specific B-Cell Response to 13-Valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With β-Thalassemia Previously Immunized With 23-Valent Pneumococcal Polysaccharide Vaccine
    Papadatou, Ioanna
    Piperi, Cristina
    Alexandraki, Krystallenia
    Kattamis, Antonis
    Theodoridou, Maria
    Spoulou, Vana
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (06) : 862 - 865
  • [40] Divergent humoral responses to 23-valent pneumococcal polysaccharide vaccine in critically-ill burn and neurosurgical patients
    Mueller, Scott W.
    Baumgartner, Laura J.
    Maclaren, Rob
    Neumann, Robert
    Wiktor, Arek J.
    Kiser, Tyree H.
    Lindberg, Gordon
    Cava, Luis
    Fish, Douglas N.
    Janoff, Edward N.
    PLOS ONE, 2018, 13 (05):
12345